Search Results

You are looking at 11 - 20 of 43 items for :

  • "kidney disease" x
Clear All
Full access

Michael B. Streiff, Bjorn Holmstrom, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, Charles Eby, John Fanikos, Randolph B. Fenninger, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Paul Hendrie, Nicole Kuderer, Alfred Lee, Jason T. Lee, Mirjana Lovrincevic, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Rita Paschal, Sanford Shattil, Tanya Siddiqi, Kristi J. Smock, Gerald Soff, Tzu-Fei Wang, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian and Anita M. Engh

, acknowledging that supporting data are limited (see VTE-C, page 1081). Renal Insufficiency and Anticoagulant Dosing in Obese Patients Chronic kidney disease and renal insufficiency are associated with obesity 88 – 92 and with an increased risk of

Full access

Laura M. Kulik

Dr. Kulik has received research support from the National Institutes of Health; National Institute of Diabetes, Digestive & Kidney Diseases; Roche Pharmaceuticals, Inc.; and Schering-Plough Research Institute. References 1

Full access

Mark D. Tyson and Sam S. Chang

increasing attention on the sequela of chronic kidney disease, there has been an impressive expansion in the use of partial nephrectomy for treating clinical T1b tumors. Although these patients technically fall within the stage I designation, most would agree

Full access

Jeffrey A. Gilreath, David D. Stenehjem and George M. Rodgers

Pharmaceuticals, Inc. ; 2009 . 22 Sinha S Chiu D Peebles G . Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients . QJM 2011 ; 104 : 221 – 230 . 23 Auerbach M

Full access

Azeez Farooki

organizations that Dr Farooki cited favor a level of at least 30 in patients with bone loss. The IOM review from 2010 suggested that a level of 20 ng/mL is sufficient for all populations. Patients with osteoporosis, chronic kidney disease, and hepatic failure

Full access

George M. Rodgers

published data using intravenous iron in patients with cancer. The 2011 NCCN Guidelines identified treatment recommendations for 4 categories of cancer patients with anemia: patients with cancer and chronic kidney disease, patients receiving

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

Hemorrhage: stool guaiac positive, endoscopy findings Hemolysis: Coombs test positive, disseminated intravascular coagulation panel positive, low haptoglobin levels, elevated indirect bilirubin Kidney disease: glomerular filtration rate less than 60 mL

Full access

Gary H. Lyman

Growth Factors also include use of the biosimilar compound epoetin alfa-epbx for the treatment of chemotherapy-induced anemia in patients receiving chemotherapy or with chronic kidney disease. Remaining Concerns Despite biosimilars passing the high bar

Full access

Javaughn Corey R. Gray, Jongho Kim, Michael Digianvittorio, Nancy K. Feeley, Paul J. Scheel, Stanley S. Siegelman, Elliot K. Fishman and Steven P. Rowe

hypertension, chronic kidney disease, anemia, and pericardial effusion initially presented with severe fatigue, cognitive impairment, and diffuse bone pain. He also reported muscle pain in his thighs and calves, diminished appetite, and severe lethargy. In a

Full access

, especially in high-risk patients. AB2014-10. Table 1: Comparison of Risk Categorization Bladder Cancer AB2014-11. Chronic Kidney Disease Epidemiology and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in